Abstract 465TiP
Background
Management of musculo-skeletal cancers patients has changed significantly with change in treatment paradigm from amputation to limb conservation. Limb Salvage Surgery (LSS) is now the standard of care. Moreover, increase in survival rates following advancement in the available multimodality treatment has lead to increased interest regarding the quality of life (QOL) and functional outcomes of the survivor patients. Unfortunately, all the QoL studies in published literature pertain to western population. This study aims to determine the functional outcomes and quality of life after performing limb salvage surgery in extremity sarcoma patients in Indian population in tertiary care hospital.
Trial design
Observational study Inclusion criteria- extremity sarcoma patients treated with either limb salvage surgery or amputation between the year Jan 2017 to Dec 2022. Extremities sarcomas includes bone tumors and soft tissue sarcomas between 14 and 50 years of age. Exclusion criteria-Non extremities sarcoma patients and patients with rotationplasty / turn-o-plasty procedures done Patients’ baseline socio-demographic and clinical characteristics (age, gender, morphology and the type of surgical intervention) as well as orthopedic or oncological complications occurring during the follow-up will be derived from the medical record. Questionnaires concerning QoL and functional outcomes which will be sent by post / telephonically or an interview with the investigators on outpatient basis. Assessment tools: Functional outcome will be measured using the Toronto extremity salvage score, Musculoskeletal tumor society score while Quality of life will be assessed using the EORTC QLQ-C30 QoL scale. Statistical Analysis: Descriptive analysis of quantitative parameters will be expressed as means and standard deviation. Categorical data will be expressed as absolute number and percentage. Independent Student's t-test will be used for testing of mean difference between independent groups. Cross tables will be generated and Chi square test will be used for testing of associations. P-value < 0.05 will be considered statistically significant. All analysis will be done using SPSS software, version 24.0.
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06
451P - The activity and safety of anlotinib combined with chemotherapy for patients with desmoid tumor: A retrospective study in a single institution
Presenter: Peng Zhang
Session: Poster viewing 06
452P - Medical and paramedical students’ awareness of environmental risk factors for cancer
Presenter: Mostafa Behery
Session: Poster viewing 06
453P - Relationship between Interleukin-6 Levels (IL-6) and COVID-19 vaccination status in cancer patients at Dr. Moewardi General Hospital, Indonesia
Presenter: Rico Hutabarat
Session: Poster viewing 06
454P - To study the prevalence of lower limb deep vein thrombosis in patients who present with stage III/IV solid tissue malignancies in Indian patients
Presenter: Oshin Suri
Session: Poster viewing 06
455P - Succinate dehydrogenase deficient GIST: Case series and review of literature from a tertiary care centre in India
Presenter: Akhil Santhosh
Session: Poster viewing 06
456P - Outcomes of COVID-19 infection in cancer patients: A single center study
Presenter: Sindhu G
Session: Poster viewing 06
457P - The effect of Interleukin-6 (IL-6) on malignancy in COVID-19 patients in Dr. Moewardi General Hospital Surakarta
Presenter: Meirisa Ardianti
Session: Poster viewing 06
458P - A real-world depiction of difficulties in applicability of IO regimens into clinical practice in metastatic setting
Presenter: Sharat Chandra Goteti
Session: Poster viewing 06
460P - The role of fluorescence-based cell-free DNA assay for detection of cancer by comparing patients with and without cancer
Presenter: Jae-Joon Kim
Session: Poster viewing 06